KP2050

KP2050 is an investigational bispecific monoclonal antibody being developed by Kira Pharmaceuticals as part of a complement-targeted pipeline for the treatment of dry age-related macular degeneration (dry AMD). It is described by the company as a bispecific biologic specifically developed for dry AMD, alongside a related asset KP1020, and is designed to modulate components of the complement cascade that drive complement-mediated retinal degeneration in geographic atrophy and earlier dry AMD. Detailed target identity, binding epitopes, and pharmacokinetic properties have not yet been publicly disclosed, and KP2050 remains at an early discovery or preclinical stage without active clinical trials.